More
    36.1 C
    Delhi
    Friday, March 29, 2024
    More

      Gene Therapy Could Be Use To Treat Pitt-Hopkins Syndrome : New Research

      Postnatal gene therapy may be able to prevent or repair many of the harmful effects of Pitt-Hopkins syndrome, a rare genetic condition, according to researchers at the University of North Carolina School of Medicine.

      This autism spectrum illness is characterise by severe developmental delays, intellectual incapacity, respiratory and movement abnormalities, anxiety, epilepsy, and moderate but identifiable facial abnormalities.

      The researchers develop an experimental gene-therapy-like strategy to help persons with Pitt-Hopkins syndrome regain normal gene function.

      In newborn mice that would ordinarily simulate the syndrome, the medicine prevent the formation of disease signs such as anxiety-like behaviour, memory deficits, and alter gene expression patterns in afflicted brain cells.

      Most genes are pass down in pairs, with one copy coming from the mother and the other from the father.

      Pitt-Hopkins syndrome occurs when one copy of the TCF4 gene is missing or mutated in a kid, resulting in a low quantity of TCF4 protein.

      Since it was first describe by Australian researchers in 1978, only about 500 cases have been recorded worldwide.

      The findings were publish in the journal eLife.

      Senior author Ben Philpot, PhD, Kenan Distinguished Professor of Cell Biology and Physiology at the UNC School of Medicine and associate director of the UNC Neuroscience Center, was quoted as saying in a release publish on the University of North Carolina School of Medicine website.

      “This first, proof-of-principle demonstration suggests that restoring normal levels of the Pitt-Hopkins syndrome gene is a viable therapy for Pitt-Hopkins syndrome, which otherwise has no specific treatment,”.

      TCF4 is a “transcription factor” gene, which acts as a master switch that regulates the activity of hundreds of other genes.

      ALSO READ  Why you should use a charcoal toothbrush to clean your teeth.

      Its disruption early in development causes a variety of developmental disorders.

      In theory, the optimum therapeutic strategy is to prevent those anomalies by restoring normal TCF4 expression as soon as feasible although this has yet to be proven.

      Philpot’s team develop a mouse model of Pitt-Hopkins syndrome in which the amount of the mouse form of TCF4 could be reliably halved.

      Many common symptoms of the illness were visible in this mouse model.

      Restoring the gene’s full activity from the beginning of embryonic life completely eliminate these symptoms.

      In these early trials, the researchers discover evidence that gene activity had to be restore in virtually all types of neurons to prevent the appearance of Pitt-Hopkins symptoms.

      The researchers then built up a proof-of-concept experiment that mimick a real-life gene therapy technique.

      The researchers utilise a virus-delivered enzyme to switch the missing expression of the mouse version of Tcf4 back on in neurons shortly after the mice were born in modified mice in which around half of the expression of the mouse version of Tcf4 was switch off.

      Analyses of the brains revealed that activity was restored over the next few weeks.

      Despite having somewhat smaller brains and bodies than normal mice, the treat animals did not exhibit many of the aberrant behaviours report in untreat Pitt-Hopkins model mice.

      The only exception was intrinsic nest-building behaviour, in which the treat mice initially appear odd but return to normal after a few weeks.

      Two other anomalies identified in untreat animals were partially restore by the treatment: change levels of TCF4-regulate genes and alter patterns of neuronal activity as determine in electroencephalograph recordings.

      ALSO READ  Researchers Develop Imaging System to Mimic Human Vision | Details Inside

      Philpot and his colleagues want to see how effective this method is in later stages of life when use to Pitt-Hopkins mice.

      They also want to develop an experimental gene therapy in which the human TCF4 gene is transferred to a Pitt-Hopkins mouse model via a virus, a therapy that could be test in children with Pitt-Hopkins syndrome in the future.

      Related Articles

      LEAVE A REPLY

      Please enter your comment!
      Please enter your name here

      Stay Connected

      18,729FansLike
      80FollowersFollow
      718SubscribersSubscribe
      - Advertisement -

      Latest Articles